Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | MASP2 | O00187 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050297 | 0.96 | SCN4A (0.42) | SCN4ARAB9APOLBIDO1CYP3A4 | |
| SCHEMBL4053215 | 0.86 | NISCH (0.42) | SCN4ARAB9APOLBALDH1A1KDM4E | |
| SCHEMBL4044619 | 0.82 | MKNK1 (0.41) | IDO1CYP3A4CDK5CDK5R1 | |
| SCHEMBL4047215 | 0.80 | CYP1A2 (0.40) | RAB9APOLBIDO1CYP3A4ALDH1A1 | |
| SCHEMBL5092536 | 0.80 | PDPK1 (0.48) | IDO1NPY5RNOTUMMAPT | |
| SCHEMBL4045984 | 0.79 | RAB9A (0.55) | RAB9APOLBALDH1A1KDM4EMAPT | |
| SCHEMBL4044196 | 0.79 | TGFBR1 (0.46) | RAB9APOLBCYP3A4CDK1GSK3A | |
| SCHEMBL1897590 | 0.78 | POLB (0.42) | SCN4ARAB9APOLBALDH1A1GAA | |
| SCHEMBL71449 | 0.78 | ESR1 (0.40) | RAB9APOLBALDH1A1MAPTHPGD | |
| SCHEMBL1899116 | 0.78 | POLB (0.48) | RAB9APOLBSCN2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752412-B | Boswellic acid derivatives and their use | 沈阳药科大学 | 2020-10-13 | — | — | CN | claimed |
| CN-107201015-B | A kind of antibacterial heat-proof polylactic acid tableware and preparation method thereof | 重庆晋豪美耐皿制品有限公司 | 2019-11-08 | — | — | CN | claimed |
| CN-101686979-A | The urea modulators that the heteroaryl of fatty acid amide hydrolase replaces | JANSSEN PHARMACEUTICA NV | 2010-03-31 | — | — | CN | claimed |
| EP-2164493-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2010-03-24 | — | — | EP | claimed |
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-05 | — | — | US | claimed |
| WO-2008153752-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-18 | — | — | WO | claimed |
| EP-1832586-A1 | Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas | Oridis Biomed Forschungs- und Entwicklungs GmbH (AT) | 2007-09-12 | — | — | EP | claimed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-108752412-B | Boswellic acid derivatives and their use | 沈阳药科大学 | 2020-10-13 | — | — | CN | disclosed |
| US-20200125564-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2020-04-23 | — | — | US | disclosed |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2020-01-28 | — | — | US | disclosed |
| CN-107201015-B | A kind of antibacterial heat-proof polylactic acid tableware and preparation method thereof | 重庆晋豪美耐皿制品有限公司 | 2019-11-08 | — | — | CN | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
| US-5616579-A | ADMINISTERING TO MAMMALS TO PREVENT GASTRIC ULCER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0562833-B1 | Anti-ulcer pyridyloxy derivatives, their preparation and uses | SANKYO CO (JP) | 1996-05-08 | — | — | EP | disclosed |
| CN-1081437-A | Antiulcer pyridine oxygen derivative, their preparation method and purposes | SANKYO CO (JP) | 1994-02-02 | — | — | CN | disclosed |
| EP-0562833-A1 | Anti-ulcer pyridyloxy derivatives, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | SCN4A 1501/4885RAB9A 1675/4885POLB 1725/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | SCN4A 3008/4885RAB9A 357/4885POLB 1747/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | SCN4A 3008/4885RAB9A 357/4885POLB 1747/4885 |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | SCN4A 747/4885RAB9A 2611/4885POLB 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.